Charged Alpha Stock Encyclopedia

Skyworks Solutions, Inc. (SWKS) Q3 FY2026 — Reported after the close July 28 (fiscal Q3 2026 ended July 3; Skyworks' FY ends October 2). Revenue $934.8M (-3.1% YoY) beat ~$920M; non-GAAP EPS $1.08 beat $1.01 but fell 18.8%; GAAP EPS $0.22 vs $0.70. The board KILLED the dividend and authorised a new $2.0B buyback. The stock fell 5.4% on the print and finished July 31 at $62.28.

The line nobody printed: free cash flow was NEGATIVE $16.7M against POSITIVE $252.7M a year earlier. Nine-month FCF fell 70% on a 2.5% revenue decline, inventory hit ~165 days, and finished goods nearly DOUBLED.

THE CALL: AVOID (4/5, THE CASH ENGINE STALLED) — base-case value ~$47.0 vs ~$62.28 today.

KEY METRICS:

- CALL: AVOID 4/5 — fair value ~$47 vs $62.28 (-24.5%). Owner earnings: FY26E non-GAAP operating income ~$825M less $224M stock comp, ~$70M restructuring, ~$20M interest, ~$165M cash taxes = ~$346M; consensus FCF $575M less stock comp = $351M. Base $400M, 6%/yr for 5 then 3%, 2% terminal at 10.5% = $41. REVERSE DCF: $62.28 demands 14%/yr for five years.

- THE PRINT — A BEAT ON A FALLING BUSINESS: revenue $934.8M vs ~$920.3M consensus, non-GAAP EPS $1.08 vs $1.01. But revenue -3.1% YoY, non-GAAP EPS -18.8%, non-GAAP operating margin -390bps to 19.4%, gross margin -220bps to 44.9%, GAAP EPS $0.22 vs $0.70.

- THE 86-CENT GAP: $0.22 GAAP becomes $1.08 via $0.35 stock comp, $0.17 deal costs, $0.23 amortisation, $0.14 restructuring — and restructuring recurs every year ($54.3M over nine months). Stock comp is NOT offset: diluted shares ROSE to 151.4M.

- THE CASH ENGINE STOPPED — the line nobody printed: FCF -$16.7M vs +$252.7M; nine-month FCF $290.2M vs $961.8M (-70%) on a 2.5% revenue decline. Inventory $1,015.5M vs $754.7M, ~165 days vs ~122. FINISHED GOODS $332.1M from $169.3M, +96%. Nine-month capex $226.0M vs $139.0M, +63%.

- THE BUYBACK IS MOSTLY A RE-AUTHORISATION: the dividend is gone (~$427M/yr, a 4.5% yield). The 'new' $2.0B program replaced the February 2025 one, which still had ~$1.2B unused. Skyworks bought ZERO shares this quarter and $7.5M over nine months vs $837.7M a year ago.

- THE MIX — WHERE THE BULL CASE LIVES: Mobile $533M (57%); Broad Markets $403M (43%), +8% YoY, Wi-Fi/data centre/auto +15%. Data centre compounds above 50%, supply- not demand-constrained. Content loss at the top customer now tracks LOW TEENS vs 20-25% guided.

- THE BALANCE SHEET: $813.8M cash vs $496.9M debt = $316.9M net cash, but cash fell $575M in nine months and a non-repeating $250.0M receivables release flattered it. ~$2.0B of debt is coming, plus ~90M new shares for Qorvo on 151.4M — about 60% dilution.

- THE MERGER AND THE GUIDE: stockholders approved, FTC compliance certified, China's SAMR at phase three (final). Combined ~$7.7B revenue, $500M+ synergies. Q4 guide $1,010-1,060M and $1.27 EPS, gross margin 44-45% — DOWN again, as mobile prices are set annually while input costs rise.

- VALUATION AND THE STREET: EV $9.11B = 12.4x FY26E non-GAAP EPS ~$5.04 but ~43x GAAP. Street is Hold, and the blended ~$72 average is STALE: post-print Citi cut to $64, TD Cowen $65, JPMorgan $65, BofA $65 (Underperform), RBC $70; only UBS raised, to $70 — average ~$66.50. We DIFFER: we charge the $224M of stock comp.

What to watch: Bullish: finished goods draining from $332M, FCF back above ~$250M next quarter, gross margin above 46%, and the Qorvo close inside the calendar year. Bearish: a second negative-FCF quarter, inventory above 170 days, or the merger slipping.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Disc Medicine, Inc. (IRON) Q2 2026 — Reported before the open on July 30 (calendar Q2 ended June 30, 2026). There is no revenue line: R&D $46.9M (+1.3%), SG&A $18.1M (+20.2%), total operating expenses $65.1M, net loss $59.5M vs $55.2M, loss per share $(1.54) vs $(1.58) on 38.69M weighted shares. Cash, equivalents and marketable securities $717.7M, runway guided into 2029. The stock closed $73.67 on July 29, rose 7.5% to $79.21 on the print, and finished July 31 at $77.00.

The line nobody printed: first-half cash used in operations was $106.4M, up 19.2% from $89.3M — the burn GREW after February's restructuring. Cash fell only $73.4M because $30.0M of the $34.0M of financing was a drawdown on the Hercules term loan. Part of the comforting cash pile is borrowed at a floor of 8.25%, secured on every asset except the intellectual property.

THE CALL: AVOID (3/5, PRICED FOR A TRIAL THAT HAS NOT READ OUT) — base-case value ~$45.0 vs ~$77.0 today.

KEY METRICS:

- CALL: AVOID 3/5 — fair value ~$45 vs $77.00 (-42%). No revenue means no DCF, so we use a scenario tree on 38.84M economic shares (38.39M common at July 23 plus 445,422 pre-funded warrants). BEAR 40%: APOLLO misses the sunlight co-primary, leaving $654M net cash plus two mid-stage antibodies = $25. BASE 45%: APOLLO hits, bitopertin approved mid-2027, ~$700M peak sales = $50. BULL 15%: APOLLO hits clean AND selcodebart and DISC-3405 deliver = $82. Weighted at an 11% discount rate = $45 ($52 at 9%, $39 at 13%). STREET: Buy — 11 buy / 0 hold / 0 sell, 11 analysts; average target ~$101.60, range $85-$125 (Morgan Stanley $85 Overweight, Stifel $94, H.C. Wainwright $118). We DIFFER and are far more CAUTIOUS.

- THE PRINT — THERE IS NO REVENUE LINE: Disc has never recorded a dollar of revenue. Q2 2026 R&D $46.933M vs $46.319M (+1.3%, flat only because more selcodebart and DISC-3405 spend offset less bitopertin manufacturing and a $10.0M milestone in the comparable quarter); SG&A $18.142M vs $15.091M (+20.2%); total operating expenses $65.075M; other income $5.612M (interest on the cash, net of loan interest); net loss $59.532M vs $55.247M; loss per share $(1.54). First half: R&D $92.837M, SG&A $41.762M, net loss $123.036M, $(3.19) per share. Accumulated deficit $633.2M against $1,279.0M of paid-in capital.

- WHAT THE FDA ACTUALLY SAID (the whole thesis): the February 13, 2026 Complete Response Letter did NOT dispute the chemistry. The FDA agreed AURORA and BEACON showed bitopertin significantly lowers whole-blood metal-free PPIX (-40.7% at 60mg vs +8.0% for placebo) and conceded strong mechanistic and biological plausibility for the biomarker. It rejected the accelerated-approval filing because the trials 'did not show evidence of association' between percent change in PPIX and the sunlight-exposure endpoints. In AURORA, time in sunlight was a PRE-SPECIFIED KEY SECONDARY endpoint and it MISSED statistical significance on a strong placebo response; only a post hoc MMRM re-analysis was nominally significant (+7.1h p=0.026 at 20mg, +8.0h p=0.013 at 60mg). The Phase 3 APOLLO trial reading out in Q4 2026 carries that same endpoint as a CO-PRIMARY alongside PPIX. The endpoint that already missed once is now one bitopertin must beat outright.

- THE BURN GREW AFTER THE RESTRUCTURING: H1 cash used in operations $106.437M vs $89.294M (+19.2%). Cash and marketable securities fell only $73.4M ($791.152M to $717.746M) because financing contributed $34.032M — of which $29.979M was debt, not equity. Q2 opex of $65.075M annualises near $260M. Thirteen days after the CRL, on February 26, the board cut roughly 20% of the workforce, a reduction the 8-K says 'primarily reflects focused workforce reductions among the Company's commercial functions'. H1 SG&A had risen $14.5M YoY, $12.6M of it personnel, explicitly for 'developing our commercialization capabilities'. SG&A then fell from $23.620M in Q1 to $18.142M in Q2, down 23% sequentially. The 'runway into 2029' is therefore computed on a company that is NOT launching anything — if APOLLO succeeds they must rebuild the commercial organisation they just dismantled.

- THE COVENANT TIED TO THE SHARE PRICE: the Hercules Capital facility allows up to $200.0M; $60.0M is drawn ($30M in November 2024, another $30M on the June 25, 2026 First Amendment). Interest is the greater of 8.25% or Prime +1.75%, interest-only through November 2028, maturing December 1, 2029, with a 6.75% end-of-term charge ($4.1M) and a first-priority lien on all assets except intellectual property. Principal due: $4.422M in 2028, $55.578M in 2029. The minimum-cash covenant is 'waived during all times that the Company's market capitalisation is greater than or equal to $1.0 billion' — switched off today at ~$3.0B, but it switches ON precisely if APOLLO fails and the equity falls roughly two-thirds. The same amendment pushed the first test date to July 1, 2028. A subjective acceleration clause carries no date at all.

- THE PIPELINE IS BETTER THAN THE ONE-ASSET FRAMING: selcodebart (DISC-0974, anti-hemojuvelin) showed a 56% major anaemia response and 72% overall response in the RALLY-MF Phase 2 in myelofibrosis anaemia, consistent across transfusion cohorts and with or without background JAK inhibitor, with hepcidin down more than 75%; presented at both ASCO and EHA, granted EU Orphan Drug Designation, with an end-of-Phase-2 FDA meeting due by year-end and further data in Q4 2026. DISC-3405 (anti-TMPRSS6) completed RESTORE-PV Phase 2 enrolment in polycythemia vera with initial data PULLED FORWARD into Q3 2026, plus a Phase 1b sickle cell readout in Q4. An expanded access programme for bitopertin launched in June. APOLLO itself enrolled 183 patients (expanded from 150) in under a year.

- THE PRICE HAS UN-PRICED THE REJECTION: IRON closed at a 12-month high of $94.11 on November 24, 2025. In October 2025 the company sold 2,619,049 shares at $84.00 (plus 59,523 pre-funded warrants) for $211.0M net — four months before the CRL. On February 13 the stock fell 21.9% to $55.95 on 5.0M shares, roughly fourteen times normal volume. It has since recovered 38% to $77.00, leaving it just 8% below that pre-rejection financing price. Beta 2.07; 50-day average $72.48, 200-day $74.77.

- VALUATION AND THE IMPLIED PROBABILITY: net cash is $717.7M less $60.0M of debt and the $4.1M end-of-term charge = $654M, or $16.84 a share. At $77.00 the market value is ~$2,991M, so the market pays ~$2,337M for the pipeline. We value the programmes unrisked at $1,150M (bitopertin), $1,000M (selcodebart) and $850M (DISC-3405); at 50%, 32% and 22% odds that is $1,082M risk-adjusted — the market is paying 2.2x our number. Base case: $654M cash + $1,035M bitopertin (unrisked x 90% approval) + $507M for the other two, less $150M corporate overhead PV and $112M expected dilution = $1,934M, or ~$50 a share. THE KEY TEST: assume APOLLO succeeds with CERTAINTY and blend the two success cases 3-to-1 and you still only get ~$58 — 25% below the price. To justify $77 you must put roughly 85% weight on the bull case in which all three programmes work. Our peak-sales assumption is not the disagreement: Morgan Stanley models peak bitopertin sales above $1B by 2035 and our $700M sits inside the Street's range. We differ on probability and discount rate.

What to watch: Bullish: a clean RESTORE-PV haematocrit-control signal for DISC-3405 in Q3, a clean end-of-Phase-2 outcome for selcodebart by year-end, or an APOLLO result that hits the time-in-sunlight co-primary outright. Bearish: APOLLO missing the sunlight co-primary even if it hits the PPIX one, an equity raise before the readout, or a further draw on the Hercules facility while $717.7M of cash sits on the balance sheet.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

IQVIA Holdings Inc. (IQV) Q2 2026 — Reported before the open on July 28 (calendar Q2 ended June 30, 2026). Revenue $4,368M (+8.7% YoY, +8.5% cc); adjusted EPS $3.15 vs $3.03 expected (+12.1%); GAAP diluted EPS $1.53 vs $1.54; adjusted EBITDA $994M (+9.2%); R&D Solutions net new bookings $3.15B (+19%, 1.22x book-to-bill); FY26 guidance raised. The stock closed $213.22 on July 27, jumped 13.9% to $242.94 on July 28, hit a 12-month closing high of $247.56 on July 29, and finished July 31 at $235.02.

The line nobody printed: GAAP income from operations was $506M — against $506M a year ago. Exactly flat, on 8.7% revenue growth, because restructuring roughly doubled ($63M vs $32M) and stock-based compensation rose 58% ($95M vs $60M). GAAP diluted EPS actually FELL.

THE CALL: AVOID (3/5, A REAL INFLECTION, ALREADY PAID FOR) — base-case value ~$190.0 vs ~$235.02 today.

KEY METRICS:

- CALL: AVOID 3/5 — fair value ~$190 vs $235.02 (-19%). Owner-earnings DCF: FY26E free cash flow ~$2.25B less ~$340M of stock compensation = $1.91B; grown 8%/yr for 5 years, then 4.5% for 5, 2.5% terminal, discounted at 8.25% = $192 (PV of 2027-2036 $17.99B + PV terminal $28.22B = EV $46.20B, less $14.09B net debt, / 167.3M diluted shares). Bear $109, bull $267; prob-weighted 25/50/25 = $190. STREET: Buy — 37 buy / 7 hold / 1 sell, 45 analysts; post-print targets $230-$288 (JPMorgan to $285 from $225, Baird to $287 from $252; TD Cowen, BofA, Barclays, BMO, Stifel, RBC and HSBC all lifted). We DIFFER and are more CAUTIOUS.

- THE QUARTER WAS GENUINELY STRONG: revenue $4,368M (+8.7% reported, +8.5% cc) vs ~$4.30B consensus and above the high end of guidance. Commercial Solutions $1,793M (+8.6% reported, ~5% organic — the best in over a year); R&D Solutions $2,575M (+8.8% reported, 7% organic, +6.7% ex-reimbursed expenses). Company-wide organic growth ~6%. Adjusted EBITDA $994M (+9.2%), adjusted net income $527M, adjusted diluted EPS $3.15 (+12.1%). CEO Ari Bousbib: 'in over 25 years of reporting earnings... I've never had as clean a quarter as this one.'

- THE BOOKINGS ARE THE STORY: R&DS net new bookings $3.15B, +19% YoY and the highest quarterly figure since 2022, for a 1.22x book-to-bill. LTM bookings $11.25B (+12.9%), rising four quarters in a row. Contracted backlog $34.2B at June 30, with ~$9.23B expected to convert to revenue in the next twelve months (+7.5%, a record). RFP flows up 'strong double digits'. Emerging-biopharma funding hit $35B in Q2, more than double a year ago; new drug launches up 45% in H1.

- THE LINE NOBODY PRINTED: GAAP income from operations was $506M — identical to the $506M a year ago, on $351M more revenue. Cost of revenues +$239M, SG&A +$65M, D&A +$16M, restructuring $63M vs $32M. GAAP diluted EPS FELL to $1.53 from $1.54. Stock-based compensation rose 58% to $95M ($160M in H1 vs $132M); IQVIA has taken a restructuring charge every year for a decade. Adjusted EBITDA margin expanded just 10 basis points (22.65% to 22.76%) — 90bps of productivity offset by 80bps of pass-through revenue — and FY26 margin is guided FLAT at about 23.2%.

- A THIRD OF THE EPS GROWTH IS THE BUYBACK: adjusted net income grew 8.4% ($527M vs $486M) but adjusted EPS grew 12.1% — the 3.7-point gap is the share count, with diluted shares down from 173.2M to 167.3M. IQVIA repurchased $398M in the quarter and $950M in H1 against H1 free cash flow of $851M (112% of the cash generated), while issuing $1,758M of new debt; cash fell from $1,980M to $1,909M. $2,819M of authorization remains.

- THE BALANCE SHEET: total debt $15,999M against $1,909M of cash = $14,090M net debt, 3.59x LTM adjusted EBITDA ($3,921M) and 4.08x gross. Q2 interest expense $197M (from $182M) consumed 39% of GAAP operating income. Goodwill $16,604M plus other intangibles $4,749M is 72% of a $29,881M balance sheet against $6,301M of equity, so tangible book is deeply negative; purchase-accounting amortisation alone was $136M in the quarter. Offsetting that: Q2 operating cash flow $558M (+26%), free cash flow $360M (+23.3%), and FY2025 free cash flow of $2,051M was 99% of adjusted net income.

- TWO THINGS FROM THE CALL ALMOST NOBODY COVERED: (1) IQVIA disclosed for the first time that emerging biopharma is 35% of R&D Solutions revenue — the highest share among large CROs. That is why bookings inflected, and it is also the highest beta to venture funding, which halved between 2021 and 2024. (2) After a competitor disclosed that 15% of its backlog sits in inactive trials, CFO Mike Fedock said IQVIA's preliminary read is 'in the ballpark of 5%' — about $1.7B of the $34.2B backlog — with a final determination due in Q3 and no impact on historical financials. On AI, management framed it as a share gain, not a threat: 294 agents across 90 use cases, 19 of the top 20 pharma companies using IQVIA AI, and large clients asking IQVIA to add thousands of FTEs in anticipation of AI-discovered molecules doubling study portfolios. Investor Day is December 2, 2026.

- GUIDANCE AND VALUATION: FY26 revenue raised to $17,275-$17,475M (midpoint growth 6.5% vs 5.8% prior — about 100bps more organic, 50bps more M&A, 80bps less FX), adjusted EBITDA $4,000-$4,050M, adjusted EPS $12.80-$13.00. Q3 guidance: revenue $4,315-$4,390M, adjusted EBITDA $1,000-$1,020M, adjusted EPS $3.19-$3.29. That revenue guide assumes ~200bps from acquisitions, leaving organic growth around 4-5%. REVERSE DCF: at $235.02 the enterprise value is $53.4B — 13.3x guided EBITDA, 18.2x adjusted EPS, 23x our $10.06 estimate of economic earnings (adjusted EPS less stock comp and recurring restructuring) and ~37x annualised GAAP EPS. At 8.25% that price asks IQVIA to compound owner earnings at 11.5% a year for five straight years. Stop charging the $340M of stock compensation and our base case becomes $241 — roughly the price. That swap IS the bull case.

What to watch: Bullish: book-to-bill holding above 1.15x for three more quarters, adjusted EBITDA margin expanding more than 50bps in a single quarter, and the Q3 inactive-backlog determination landing at or below 5%. Bearish: emerging-biopharma funding rolling over, an inactive-backlog figure above 10%, or another quarter of flat GAAP operating income while stock compensation compounds at 50%.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Woodward, Inc. (WWD) Q3 FY2026 — Reported at 4:00pm ET on July 29 (fiscal Q3 ended June 30, 2026). Net sales $1,109.7M (+21% YoY); adjusted EPS $2.52 vs $2.44 expected (+43%); GAAP EPS $2.40; gross margin 31.5% from 27.2%; record segment margins in both businesses; FY26 adjusted EPS guidance raised to $9.30-$9.50. The stock closed $385.42 on July 29, fell 7.6% to $356.28 on July 30, and closed $360.75 on July 31.

Take the raise apart: FY26 guidance of $9.30-$9.50 less the $6.96 already banked in nine months implies a Q4 of $2.34-$2.54 — a $2.44 midpoint that is BELOW the $2.52 just reported, with the sales guide not raised at all.

THE CALL: AVOID (4/5, EXCELLENT COMPANY, EXTRAORDINARY PRICE) — base-case value ~$168.0 vs ~$360.75 today.

KEY METRICS:

- CALL: AVOID 4/5 — fair value ~$168 vs $360.75 (-53%). Base DCF $160 at 9% (6% sales CAGR to $7.75B, FCF margin 7.5% to 11.5%, 3% terminal, 61.0M diluted shares, $867M net debt); bear $98, bull $257; prob-weighted 25/50/25 = $168. STREET: Buy — 12 buy / 8 hold / 1 sell, 21 analysts, average target $431.67 (range $408-$470, +20%); RBC reiterated Outperform the next morning. Even the LOW target is 13% above the price. We DIFFER, sharply.

- THE QUARTER WAS GENUINELY EXCELLENT: net sales $1,109.7M (+21%); Aerospace $708.7M (+19%), Industrial $401.0M (+26%). Gross margin 31.5% from 27.2% — 430bps in a year. EBIT $207.7M (+51%), adjusted EBIT $217M (+58%), adjusted EBITDA $249M. Aerospace segment margin 24.0% (+290bps), Industrial 22.1% (+720bps). Both records. Adjusted EPS $2.52 (+43%) on a $9.3M restructuring charge (the whole GAAP-to-adjusted gap).

- THE SENTENCE THAT DID THE DAMAGE: on the call, management said future margin expansion should come increasingly from productivity, automation and lean — NOT pricing — because pricing normalises to a typical 3-5% a year. The release names price first or second in BOTH segment explanations: Aerospace rose on 'price realization and increased leverage on higher sales volumes'; Industrial 'primarily driven by increased leverage on higher sales volume and price realization'.

- THE GUIDE IMPLIES A DECELERATION: FY26 adjusted EPS $9.30-$9.50 less $6.96 YTD = a Q4 of $2.34-$2.54, midpoint $2.44 — below the $2.52 just printed, in the seasonally biggest quarter. Sales growth guidance was left unchanged at +20-23%, so implied Q4 sales are ~$1.14B, roughly +14% against +21% in Q3. Adjusted tax rate guidance went UP to ~22.5%. FY25 was $3,567M of sales and $6.89 adjusted EPS.

- A FIFTH OF THE EARNINGS GROWTH IS CHINESE TRUCKS: Industrial's quarter includes $40M of China on-highway natural gas truck sales, up ~142% YoY. Management's own bridge attributes 90bps of Industrial's 720bp margin expansion and $0.14 of Q3 EPS growth to it; across nine months, $53M of sales (+113%) and $0.42 of the $2.16 adjusted EPS growth. Woodward's 10-K lists 'volatility with respect to the China on-highway natural gas truck market' as a named risk factor.

- THE CASH WENT THE OTHER WAY: Q3 operating cash flow $147M (+17%) but capex $59.6M (+125%), so free cash flow FELL 12% to $87M while adjusted net earnings rose 42%. FY26 FCF guidance was left UNCHANGED at $300-350M and capex at ~$290M (about 3x depreciation), with heavier Q4 spend on Spartanburg and A350 spoiler machinery. That is ~56% conversion of adjusted earnings and a ~1.5% FCF yield. Nine-month buybacks were $553M vs $124M a year ago; short-term debt went $122M to $592M; equity FELL despite $414M of earnings. Leverage is still a comfortable 1.6x.

- REVERSE DCF: at $360.75 the enterprise value is $22.4B — about 38x FY26 adjusted EPS and 26x EBITDA. At 9% with 3% terminal growth, that price requires Woodward to compound sales at ~12% a year for TEN YEARS (tripling to ~$13.5B) while DOUBLING FCF margin to 15%. It has compounded at about 8% a year over the last decade. Also worth knowing: Defense OEM fell 6% to $141M, the only end market that shrank, and the effective tax rate stepped from 14.5% to 24.2% — pre-tax earnings grew 53%, net earnings 35%.

What to watch: Bullish: a Q4 above $2.54, Aerospace margin holding 24% into FY27 with pricing already normalised, FCF conversion clearing 70% once Spartanburg is done. Bearish: Industrial margin back below 19%, any air pocket in China on-highway natural gas trucks, or Defense OEM staying negative.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Impinj, Inc. (PI) Q2 2026 — Reported after the close on July 29 (quarter ended June 30, 2026). Revenue $108.4M (+11% YoY) vs a $103-106M guide; non-GAAP EPS $0.86 vs ~$0.80 (GAAP $0.39); adjusted EBITDA $30.7M; non-GAAP gross margin 60.9% — all records. The stock closed +5.9% at $147.49 on July 30, then $151.36 on July 31.

The record is partly a calendar artifact: ~$17.0M of the $108.4M is the annual NXP patent licence, which the 10-Q says is recognised IN THE SECOND QUARTER OF EACH YEAR at essentially no cost.

THE CALL: AVOID (4/5, GREAT COMPANY, IMPOSSIBLE PRICE) — base-case value ~$89.0 vs ~$151.36 today.

KEY METRICS:

- CALL: AVOID 4/5 — fair value ~$89 vs $151.36 (-41%). Base DCF $83 at 10.5%; bear $32, bull $158; prob-weighted 25/50/25 = $89. STREET: Buy, honest consensus ~$180 (+19%). Published targets are stale — aggregators quote $190-$241, many set last October at $240. Dated and named post-print: Jefferies RAISED to $190, Needham CUT to $168, both Buy; UBS Neutral, Evercore In Line. We DIFFER.

- THE $17M THAT MADE THE RECORD: the annual NXP licence is booked entirely in Q2 each year at ~100% margin — 16% of revenue and 7.3 of the 60.9 gross-margin points. CFO Cary Baker: 'excluding licensing revenue, second quarter product gross margin was 53.6%' (vs 52.6%) and 'adjusted EBITDA margin was 15%' (vs the 28.3% headline). Product revenue was $91.4M, not $108.4M.

- NXP CAN CANCEL IT: the 10-Q says NXP pays annually until the Indicator Patents expire 'in about 2034' or 'until NXP earlier terminates', and may terminate 'on any April 1' once it designs out all valid claims. The fee escalates yearly. That $17M is ~55% of the record $30.7M adjusted EBITDA — a third of FY26 cash earnings, sitting in a competitor's option.

- EPS GUIDED DOWN 30% ON FLAT REVENUE: Q3 revenue $105.5-108.5M but non-GAAP EPS $0.59-0.63 vs $0.86 and adjusted EBITDA $20.7-22.2M vs $30.7M. The cheque does not repeat and opex rises. In fairness, Baker framed Q3 against '$91.4 million product revenue... a 17% quarter-over-quarter increase at the midpoint' — the product business is genuinely accelerating.

- THE YEAR STARTED NOWHERE: Q1 2025 revenue $74.28M; Q1 2026 $74.25M — identical, with a $15.2M GAAP operating loss. The celebrated +46% sequential jump is measured off that. H1 2026 is a GAAP net loss of $13.0M and operating loss of $4.7M. FY2026E ~$388M, about +7% on 2025's $361.1M.

- FREE CASH FLOW IS FUNDED BY STOCK: SBC was $31.0M in H1 (~$62M annualised, 16% of revenue) vs ~$55M of 2026E free cash flow; 2025 was $45.9M FCF vs $55.3M SBC. Basic shares went 29.0M to 30.5M (+5.1%) in a year. From GAAP operating income, owner earnings are ~$0. Also: three unnamed customers are 61% of revenue; net cash is only ~+$16M after $247.3M of converts.

- REVERSE DCF: at $151.36 (EV ~$4.6B, 11.9x 2026E sales), at 10.5% with 3% terminal growth and a 22% terminal owner-earnings margin, the price needs ~25% revenue growth a year for TEN YEARS — to ~$3.5B. Impinj has compounded at 19% over six years and will do ~7% this year. GENUINELY GOOD: record bookings a 2nd straight quarter, record units, an empty channel into an H2 restock, R&D at 27% of revenue, ~200bps of M800 margin to come.

What to watch: Bullish: a clean Q1 2027 (the test the CFO set himself), product revenue over $110M, a disclosed solutions revenue line. Bearish: a third straight Q1 miss, or any sign NXP is terminating the licence.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Sonos, Inc. (SONO) Q3 FY2026 — Reported after the close July 29 (quarter ended June 27, 2026). Revenue $375.3M (+8.8%), non-GAAP EPS $0.27 vs ~$(0.02) expected, adjusted EBITDA $44.0M (+24%), GAAP gross margin 50.4% vs non-GAAP 45.5%. The stock had run 19% into the print to $17.52, then fell 17.6% to $14.43 and closed the week at $14.66.

GAAP gross margin came in ABOVE non-GAAP — 50.4% vs 45.5% — because $23.2M of IEEPA tariff refunds hit cost of revenue. Strip it out and $31.5M of operating income becomes ~$8.4M from actually selling speakers. And the memory bill goes $14M to $35M next quarter.

THE CALL: HOLD (3/5, A REAL BEAT, AND A MARGIN RESET THE PRICE HASN'T FINISHED ABSORBING) — base-case value ~$13.2 vs ~$14.66 today.

KEY METRICS:

- CALL: HOLD 3/5 — fair value $13.20 vs $14.66 (-10%). STREET: thin, only TWO live targets — Rosenblatt Buy $21 (Jul 30), Morgan Stanley Hold $18 (May, not revised). Avg ~$19.50 (+33%). We DIFFER: Rosenblatt's $21 rests on 12x EV/CY26 EBITDA ≈ $190M — assuming the memory hit basically doesn't happen.

- THE BACKWARDS MARGIN: GAAP gross margin 50.4% came in ABOVE non-GAAP 45.5%, because $23.2M of IEEPA tariff refunds hit cost of revenue (+~620bps). Sonos honourably excluded it from all non-GAAP. But of $31.5M GAAP operating income, $23.2M was the refund — only ~$8.4M (2.2% margin) came from selling speakers.

- THE MEMORY CURVE: AI data-centre demand repriced DRAM. Gross-margin hit ~200bps in Q2, ~380bps ($14M EBITDA) in Q3, guided ~1,000bps / $35M in Q4. Ex-memory, Q3 adjusted EBITDA would have been $58M (+64%). Q4 GAAP GM guided 39-41% vs 50.4% delivered; Q4 EBITDA midpoint just +$3M.

- THE FY27 SENTENCE THAT BROKE THE STOCK: CFO Saori Casey said the LOW END of the Q4 GM range is a reasonable framework for ALL of FY2027 — ~40% vs ~44% this year, H1 worse, opex flattish. On ~$1.6B revenue that's ~$64M of profit gone, taking adjusted EBITDA from $181M toward ~$138M.

- GROWTH RE-ACCELERATED: +2% in H1 to +8.8%. EMEA +17.4% ($114.2M), APAC +27.2% ($22.7M), Americas only +3.8% ($238.4M). Speakers +12.5% to $285.3M, 76% of revenue (Sonos Play + Era 100 SL, first new speakers in ~16 months). System products -5.4%: the top ASP tier still shrinking.

- THE BUYBACK IS A TREADMILL: $95.3M spent over nine months = ~5.5% of market cap, yet weighted-average BASIC shares fell only 120.8M to 119.9M (under 1%), because $46.4M of stock comp flowed back. Only $35M left on the authorisation.

- BALANCE SHEET IS THE FLOOR: $206.9M cash + $54.1M securities = $261.0M net cash, ZERO debt — ~15% of market cap, so EV ~$1.51B. Nine-month operating cash flow $144.2M less $16.7M capex = $127.5M FCF, though ~$24M of that was tariff cash.

- GOVERNANCE, TWO EVENTS IN 24 HOURS: CFO Saori Casey announced her retirement on the call (stays until a successor is named; no dispute). July 28 the board went 10 to 11, seating Chris Shackelton of Coliseum Capital, the largest holder. On the app debacle: no NPS disclosed.

- VALUATION: owner earnings = adjusted EBITDA less stock comp, capex and cash tax (stock comp counts because $95M of buybacks moved the count under 1%). FY26 ~$81M; on the ~40% GM framework FY27 falls to ~$43M. DCF at 10.5%: base $14.06, bear $7.66, bull $19.21; weighted 30/50/20 = $13.17. REVERSE DCF: $14.66 demands ~$121M of owner earnings now vs ~$81M FY26.

What to watch: Bullish: a price rise that sticks (5% ≈ $80M of gross profit, offsetting most of the memory hit), spot DRAM rolling over, system products back to growth. Bearish: Q1 FY27 gross margin under 38%, a price rise that costs volume, or growth slipping back to ~2%.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Sanofi (SNY) Q2 2026 — Reported before the European open on July 30 (quarter ended June 30, 2026). Q2 net sales EUR 11,597M, +17.8% at constant exchange rates and +16.0% reported. Business EPS EUR 2.09 per ORDINARY share, +33.3% CER. Business operating income EUR 3,291M at a 28.4% margin, up 380bps. Q2 free cash flow EUR 2,670M, +86.8%. And FY2026 guidance was RAISED to around +10% sales growth at CER. But IFRS net income fell 91.3% to EUR 343M, and Sanofi discontinued THREE development programmes in the same release. SNY closed down 4.4% at $42.89 on the day, then $43.08 on July 31 — 17.7% below the November high.

Sanofi reports in EUROS per ORDINARY share, and 1 ordinary share = 2 SNY ADSs. So the EUR 2.09 business EPS everyone quoted is about $1.22 per ADS at Sanofi's own 1.163 EUR/USD rate. On consensus FY2026 business EPS of EUR 8.54 per ordinary share, SNY trades at roughly 8.7x — the cheapest large-cap pharma on earth — while paying a ~5.6% dividend. The catch: Dupixent is 44.4% of ALL sales, roughly half its profit belongs to Regeneron, and the pipeline meant to replace it lost three programmes in one quarter.

THE CALL: BUY (4/5, PAID TO WAIT ON A REAL PIPELINE PROBLEM) — base-case value ~$55.0 vs ~$43.08 today.

KEY METRICS:

- CALL: BUY 4/5 — fair value ~$55 per ADS vs $43.08 (+27.7%). STREET (S&P Global, 10 analysts): consensus Buy, average target $54.61, median $54.50, range $45-$63. We ALIGN almost to the dollar — but for a different reason. Their case is the pipeline; ours is that at 8.7x you are not paying for the pipeline at all.

- ADR BASIS (this is where most coverage goes wrong): 1 Sanofi ordinary share = 2 SNY ADSs. Sanofi reports EPS, dividends and share counts per ORDINARY share, in EUR. Q2 business EPS EUR 2.09/ordinary = EUR 1.045/ADS = ~$1.22 at Sanofi's own Q2 average rate of 1.163. FY2025 dividend EUR 4.12/ordinary = ~$2.40/ADS = a 5.6% yield. 1,196.6M ordinary shares = ~2,393M ADSs = ~$103B market cap.

- THE PRINT: Q2 net sales EUR 11,597M (+17.8% CER, +16.0% reported, FX -1.8pp). US EUR 6,344M +33.5%; Europe EUR 2,141M +1.3%; RoW EUR 3,112M +3.7%; China EUR 676M -4.9%. Business gross margin 79.6% (+190bps). SG&A +9.0% against +17.8% sales. BOI EUR 3,291M, 28.4% margin (+380bps). Business net income EUR 2,501M. Tax rate 21.7%.

- THE EUR 1,972M NOBODY NETS OUT: Dupixent did EUR 5,154M (+37.6%), above EUR 5B in a quarter for the first time, and is 44.4% of ALL Sanofi sales. But it came out of the Regeneron collaboration — Sanofi books 100% of the revenue and shares roughly half the profit. Q2 profit-sharing back to Regeneron: EUR 1,972M, up from EUR 1,360M. Net alliance drag EUR 1,850M = 16.0% of group revenue. Model Sanofi off the revenue line and you model a company that does not exist.

- THE QUARTER THEY KILLED THREE DRUGS: amlitelimab (OX40L, atopic dermatitis) will not go to submission despite a POSITIVE long-term extension; itepekimab (COPD, with Regeneron) discontinued; balinatunfib (oral TNF) failed interim analyses in Crohn's and UC. Impairment EUR 1,031M, of which EUR 952M was amlitelimab. R&D rose 17.9% to EUR 2,233M including >EUR 200M of WIND-DOWN costs. Dupixent also missed both phase 3 primary endpoints in lichen simplex chronicus.

- VACCINES IS QUIETLY BREAKING: total vaccines EUR 1,150M, -4.7%. Influenza/COVID -61.7% to EUR 54M. Meningitis/travel/endemic -5.9%. The polio-pertussis-hib franchise grew only 1.4% — and only because Sanofi BOUGHT Heplisav-B (Dynavax), which lifted US sales 77.2%; RoW fell 21.2% on declining Chinese childbirths. Only Beyfortus grew properly, +54.2% to EUR 108M.

- BALANCE SHEET: net debt EUR 10,988M on Jan 1 to EUR 15,513M on Jun 30 — up EUR 4.5B in six months (Dynavax -EUR 1,635M, dividend -EUR 4,923M, buyback -EUR 1,009M, FX -EUR 194M, Opella -EUR 220M). Cash EUR 6,350M. EUR 2.3B of notes issued in April at 3.00%/3.375%/3.75%. The EUR 1B buyback is COMPLETE with no successor announced. Intangibles + goodwill EUR 68.3B = 53% of total assets.

- GUIDANCE + 2030: FY2026 sales now expected to grow around 10% at CER (upgraded), with business EPS growing slightly faster at CER; FX c.-1% on sales and c.-2% on EPS. 2030 ambitions restated in writing: Dupixent ~EUR 25B and pharma launches ~EUR 10B, both at CER. Launches did EUR 1,305M in Q2, +48.3%. New CEO Belen Garijo took over at the close of the AGM on April 29, 2026; this is her first full quarter.

- VALUATION: owner earnings = Sanofi's own free cash flow. FY2025 EUR 8,089M; H1 2026 EUR 3,724M (+51.5%), EUR 2,670M in Q2 alone; we carry EUR 8.8B for 2026E. Grow 6% for five years, apply a 20% haircut to terminal cash flow for the Dupixent exclusivity cliff, 1.25% terminal growth, 8.75% discount rate: EV ~EUR 124.4B, less EUR 15.5B net debt, plus ~EUR 5B for the retained 48.2% Opella stake = EUR 113.9B equity = EUR 95.2/ordinary = EUR 47.6/ADS = ~$55.40. Bear $41 (only 5% below the price), bull $70. REVERSE DCF: at $43.08 the EV of ~EUR 99B asks for only EUR 7.4B of free cash flow forever — 16% BELOW what Sanofi earns this year, with zero real growth ever again.

What to watch: Bullish: the launch basket clearing EUR 1.5B per quarter, venglustat approved in type 3 Gaucher by the Nov 25 PDUFA date, or a new buyback authorisation. Bearish: any walk-back of the 2030 ambitions (Dupixent ~EUR 25B, launches ~EUR 10B), another pipeline discontinuation of size, or vaccines declining again in the seasonally biggest fourth quarter.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Madison Air Solutions Corporation (MAIR) Q2 2026 — Reported the MORNING of July 30 (quarter ended June 30, 2026). Net sales $991.3M (+21.0% GAAP, +14% pro forma, +14.1% organic), adjusted EBITDA $265.8M at a 26.8% margin (DOWN from 27.5%), GAAP EPS $0.15 vs $0.31 adjusted, backlog $2,868.4M (+133.0%). FY26 sales guidance RAISED $75M to $3,825-3,925M while adjusted EBITDA guidance was REAFFIRMED unchanged at $1,020-1,065M. The stock closed down 7.9% at $29.14 (low $28.69 intraday, the widely-quoted -9.3%), then $29.06 on July 31 — the lowest close of its public life.

Four numbers in circulation are wrong. The $0.31 EPS is ADJUSTED, not GAAP ($0.15), and the '$0.00 prior year' is a carve-out artifact (it was $0.07). 'Resilient residential' is false: Residential ORGANIC sales FELL 4.8%. And tariffs were a Q2 TAILWIND, not a headwind — the Supreme Court voided them in February and MAIR booked refunds as a reduction to cost of goods sold.

THE CALL: HOLD (3/5, A FAIR PRICE FOR A REAL BUSINESS WITH A MARGIN QUESTION) — base-case value ~$31.0 vs ~$29.06 today.

KEY METRICS:

- CALL: HOLD 3/5 — fair value $31 vs $29.06 (+6.7%). STREET: Buy, 5 buy / 0 hold / 0 sell, but only ~5 firms cover it. Average target $44.63, median $45. Stifel CUT to $41 from $49 on 7/31 (the only post-print revision), RBC $47 (cut from $50), Wells Fargo $46 (cut from $47). We DIFFER: their $44.63 implies 24.2x EV/EBITDA — a Trane multiple.

- THE REAL STORY: sales guidance RAISED $75M at the midpoint to $3,825-3,925M, adjusted EBITDA guidance REAFFIRMED unchanged at $1,020-1,065M. That is an implied FY margin cut from 27.43% to 26.90%, 53bps. More revenue at zero incremental profit. The market read it correctly.

- COMMERCIAL INCREMENTAL MARGIN 13.5%: Commercial sales +$126.5M (+23.8%, 22.3% organic) but Commercial adjusted EBITDA only +$17.3M. Segment margin fell from 29.3% to 26.3%, down 303bps. Management: the comparison 'primarily reflects rapid growth in large data center programs, project mix, capacity addition investments and program ramp costs'. The record backlog and the lost margin are the SAME event.

- RESIDENTIAL IS NOT RESILIENT: reported +16.2% but ORGANIC sales FELL 4.8% (-3.4% for the half). AprilAire contributed $56.4M against a $46.5M total increase. Residential backlog FELL from $71.5M to $66.0M. Its margin rose 423bps to 29.5% — but $21.8M of the $25.9M EBITDA gain was AprilAire, plus 'favorable net tariff impacts'.

- TARIFFS WERE A TAILWIND: the Supreme Court invalidated certain emergency-authority tariffs in Feb 2026; MAIR began receiving REFUNDS in Q2 and booked them as a reduction to cost of goods sold. Adjusted gross margin STILL fell 120bps to 39.0%. Underlying margin is worse than printed, and the help does not repeat.

- THE Q4 BET: guidance implies H2 margin of 27.72% vs 26.07% delivered in H1. Management guided Q3 'roughly flat'. Hold Q3 at Q2's 26.8% and Q4 must print ~28.6% — the highest margin ever disclosed, 180bps above the quarter just reported.

- SHARE COUNT + STRUCTURE: 10-Q cover 7/28/26 — Class A 177,342,753 + Class B 324,379,859 = 501,722,612 shares, both fully economic (Class B is 10 votes, not a stub). Market cap $14.58B, net debt $2,791.9M ($3,053.7M debt less $261.8M cash), EV $17.37B = 16.7x FY26E EBITDA. Holdings (founder Larry Gies) has 64.7% of economics and 95.2% of votes.

- UNUSUALLY CLEAN FOR A SPONSOR IPO: NO Tax Receivable Agreement at all. And the control block is NOT a 180-day cliff — the prospectus discloses TWO-YEAR lock-ups with Holdings and Kedge running to ~April 2028. Backlog $2,868.4M (+133.0%), book-to-bill 1.34x (1.51x Commercial), net leverage 2.8x after repaying $2,625.7M with IPO proceeds.

- VALUATION: 2027E sales ~$4.19B at 27.0% = $1.13B EBITDA, less $50M recurring equity comp (the 10-Q shows $93.0M unrecognised over 2.65 yrs), $55M real depreciation, $175M cash interest, tax 25% = owner earnings ~$637M, or $1.27/share. DCF at 9.0% = $28 (bear $19, bull $40). Peer cross-check 16-18x = $28-32. Fair value $31. The REVERSE DCF at $29.06 demands ~$656M of 2027 owner earnings vs our $637M — almost exactly fair.

What to watch: Bullish: Q4 adjusted EBITDA margin above 28%, Commercial incremental margins back above 20%, Residential organic sales returning to growth. Bearish: Q3 margin below 26%, any cut to the FY adjusted EBITDA range, or Commercial backlog converting at falling margins into 2027.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Arxis, Inc. (ARXS) Q2 2026 — Reported AFTER the close on July 29. Revenue $500.7M (+25.0%, 21.0% ORGANIC), adjusted EBITDA $211.5M (+37.6%) at a 42.2% margin, GAAP net LOSS $(4.9)M / EPS $(0.01) vs $0.28 adjusted, FCF $127.3M (+261%), FY26 guidance RAISED 10%. The stock then rose 27.9% in two sessions to an all-time high.

Two things nearly every write-up got wrong: the market cap (feeds showing ~$2.2B use only the 40.5M IPO shares — it is really $22.7B on 417.5M), and the $(0.01)-to-$0.28 gap, which is IPO stock comp of which ~$120M/yr RECURS.

THE CALL: REDUCE (3/5, AN EXCEPTIONAL BUSINESS AT AN UNFORGIVING PRICE) — base-case value ~$40.0 vs ~$54.3 today.

KEY METRICS:

- CALL: REDUCE 3/5 — fair value $40 vs $54.30 (-26%). STREET: Moderate Buy (12 analysts, 10 buy / 2 hold) yet the $49.64 average target is already 8.6% BELOW the price. Jefferies $55, Baird $55, Citi $54, RBC $50, Morgan Stanley $50, Wolfe $43, Redburn $40. We DIFFER on rating, ALIGN on price.

- SHARE-COUNT TRAP: 10-Q cover 6/30/26 — Class A 76,797,587 + Class B 340,676,783 = 417,474,370 shares, BOTH economic (diluted WASO 401,813,695). Market cap $22.7B, NOT the ~$2.2B feeds show (= 40.5M IPO shares x $54.30). Net debt $1,239M, EV $23.9B.

- THE PRINT: revenue $500.728M (+25.0%); gross margin 52.4% vs 49.3%; operating income FELL to $32.684M from $82.853M; net loss $(4.909)M, EPS $(0.01). Adjusted EBITDA $211.498M (+37.6%), 42.2% margin vs 38.4%. Adjusted EPS $0.28. FCF $127.298M (+261%). FY26 guide raised to $790-800M EBITDA.

- THE $(0.01)-TO-$0.28 BRIDGE: net loss $(4.909)M + stock comp $107.111M + intangible amortisation $36.284M + other $11.812M (incl $13.3M TRA) + deal costs $2.534M - tax $(39.625)M = $113.207M. We grant the amortisation and the one-time IPO charge; NOT the ~$120M/yr that RECURS ($239.019M unrecognised over 2.5 yrs + a $129.680M convertible grant over 5).

- GROWTH & BALANCE SHEET: organic +21.0% ($83.9M of the $100.3M gain), M&A ~4pts; volume mid-teens, pricing mid-single-digit. The release leads with Defense & Space but the 10-Q says growth was 'led by Industrial Technology'. Net leverage 1.8x from 4.2x; tangible book NEGATIVE ~$780M; TTM GAAP net income +$128.0M.

- OCTOBER 13: the company's own risk factors state the IPO lock-ups EXPIRE 10/13/2026, when 340.7M Class B shares — 82% of the company, held by sponsor Arcline — become sellable against a 76.8M-share float. Arxis has also elected Nasdaq 'controlled company' status.

- VALUATION: 2027E EBITDA ~$950M -> ~$600M FCF -> ~$480M owner earnings after the ~$120M/yr of recurring stock comp. DCF at 9.5% = $31 (bear $17, bull $52; weighted $32); 21x 2027 EV/EBITDA = $45; fair value $40. At $54.30 that is 35.7x TTM EBITDA and 25.2x 2027E. The REVERSE DCF demands ~$807M of 2027 owner earnings vs our $480M.

What to watch: Bullish: Oct 13 lock-up passing with no Class B block, organic growth above 15% for two more quarters, FY27 EBITDA guided above $1.0B. Bearish: organic growth below 10%, a Class B secondary/block trade, or FY27 EBITDA guided under $900M.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Imperial Oil Limited (IMO) Q2 2026 — Imperial Oil reported Q2 2026 (quarter ended June 30) before the open on July 31. ALL COMPANY FIGURES ARE IN CANADIAN DOLLARS; the NYSE American quote is in USD. Net income C$2,190M vs C$949M (+130.8%), diluted EPS C$4.52 vs C$1.86, total revenues C$16,062M (+43.0%), free cash flow C$2,234M (+125%). No identified items. The stock closed US$128.80 -> US$129.57, about +0.6%.

Net income more than doubled, but WTI averaged US$92.69 in the quarter against US$63.69 a year ago — up 45.5%. Underneath that price the operations went BACKWARDS: production fell to 414 kboe/d from 427, Kearl fell 7%, upstream unit cash costs ROSE 11.8% to C$32.41/boe, and Imperial CUT full-year refinery utilisation guidance from 91-93% to 85-88%. Management is now accelerating a 5% buyback (24,179,635 shares, ~C$4.4B) to complete before year end — after repurchasing NOTHING in Q1 or Q2, at a price within 7% of an all-time high.

THE CALL: REDUCE (3/5, A GREAT COMPANY AT A PEAK-CYCLE PRICE) — base-case value ~$101.0 vs ~$129.57 today.

KEY METRICS:

- OUR CALL: REDUCE 3/5 — fair value C$142 (~US$101) vs the C$181.64 close (US$129.57), about -22%. Street: Hold, and already cautious — 22 analysts, 4 buy / 10 hold / 8 SELL, average target ~C$151 (-17%). TD Securities: Sell, C$156. Scotiabank: Sector Perform, C$159 (raised from C$151). We ALIGN with the Street directionally and go further.

- CURRENCY: Imperial reports in CANADIAN dollars; the shares trade in USD. C$4.52 diluted EPS converts to ~US$3.27 — if your data feed showed 3.27, it converted and didn't say so. US$129.57 x CADUSD 0.7133 = C$181.64.

- THE PRINT (C$): net income 2,190 vs 949 (+130.8%); diluted EPS 4.52 vs 1.86; revenues 16,062 vs 11,232 (+43.0%); cash from ops 2,704 vs 1,465; FREE CASH FLOW 2,234 vs 993 (+125%); capex 531. No identified items in either year. Segments: Upstream 1,299 (vs 664), Downstream 787 (vs 322), Chemical 65 (vs 21), Corporate +39 (vs -58). H1 net income 3,130 = 96% of ALL of 2025.

- WHY: WTI averaged US$92.69 vs US$63.69 (+45.5%). Bitumen realisation C$95.79/bbl (+C$29.97); synthetic crude C$141.10 (+C$53.25, +61%). WCS US$77.90; WTI/WCS spread US$14.79.

- OPERATIONS WENT BACKWARDS: production 414 kboe/d vs 427; Kearl 182 vs 195 (absence of exceptional high-grade ore); Syncrude 73 vs 77 (extreme rainfall); Cold Lake 149 vs 145. Refinery utilisation 76% vs 87% (planned Strathcona turnaround); throughput 331 vs 376 kbd. Upstream unit cash cost C$32.41/boe vs C$29.00 (+11.8%); Syncrude C$57.81 vs C$46.95 (+23%).

- GUIDANCE CUT: full-year refinery throughput 395-405 -> 370-380 kbd; utilisation 91-93% -> 85-88%, for unplanned downtime and a Strathcona rail logistics issue targeted to resolve by year end.

- BUYBACK: NCIB renewed June 29 2026 for up to 24,179,635 shares (5%), and management will ACCELERATE to complete it before year end — roughly C$4.4B at C$181.64. Zero shares were repurchased in Q1 OR Q2 2026. ExxonMobil (69.6%) participates pro-rata to hold its stake. Diluted shares 484.9M, down ~27% from ~664M in mid-2022.

- BALANCE SHEET: total debt C$3,988M, cash C$2,839M, net debt C$1,149M — effectively debt-free. Equity C$24,543M, total assets C$47,863M. Q3 dividend C$0.87 declared (+21% y/y), a 1.92% yield — thin for an integrated at a cycle peak.

- VALUATION: mid-cycle owner earnings ~C$4,780M (C$9.86/sh) = mid-cycle net income C$4,600M + D&D C$2,080M - sustaining capex C$1,900M, normalised to ~US$75 WTI. DCF at 8.5% / 1.5% terminal: base C$144, bear (US$65 oil) C$90, bull (US$85) C$200. Weighted 55/20/25 = C$142. REVERSE DCF: at C$181.64 the EV of C$89.2B demands ~C$6.02B of owner earnings forever — 80% of the best year in company history (2022: C$7,340M), implying WTI near US$85 permanently.

- CYCLE CONTEXT: net income 2022 C$7,340M -> 2023 C$4,889M -> 2024 C$4,790M -> 2025 C$3,268M. Annualising this quarter gives ~10x earnings; 2025's actual C$6.48 EPS gives ~27x. Same assets — the barrel is the variable.

- UNDER-COVERED: a non-binding trilateral MOU (Canada + Alberta + Oil Sands Alliance) was signed AFTER quarter-end, the vehicle for the stalled Pathways carbon-capture project. Real option, unknowable timing — nothing in our numbers assumes it.

What to watch: Bullish: refinery utilisation back above 88% with the Strathcona rail constraint resolved, upstream unit cash costs back below C$30/boe for two consecutive quarters with Kearl above 190 kbd, and the Pathways trilateral MOU converting into definitive agreements. Bearish: WTI averaging below US$70 in Q3, the NCIB completed in full above C$180, or full-year refinery utilisation landing at/below the new 85% floor.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.